Atopic Dermatitis Market To Reach USD 18.6 Billion By 2032 Report By DataHorizzon Research

Advertisement

Growing cases of skin disorders contribute to drug approvals and the need for organic medications.

Fort Collins, Colorado, March 14, 2024 (GLOBE NEWSWIRE) — The Atopic Dermatitis Market size was valued at USD 9.1 Billion in 2023 and is expected to reach a market size of USD 18.6 Billion by 2032 at a CAGR of 8.3%. 

Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by itching, redness, swelling, and skin cracking. The rising prevalence of atopic dermatitis can be attributed to various factors, including genetic predisposition, environmental influences, and lifestyle choices, among others. This increasing prevalence worldwide is expected to drive market growth in the forecast period. For instance, according to a report by the International League of Dermatological Societies (ILDS), in 2022, approximately 223 million individuals were living with atopic dermatitis, with around 43 million falling within the age range of 1 to 4.

Advertisement

The growing number of approved products for treating atopic dermatitis reflects significant medical research and pharmaceutical innovation advancements. Emerging treatments such as topical creams, oral medications, and biological therapies offer a broader spectrum of options for managing the condition. With a wider array of effective treatments available, individuals affected by atopic dermatitis are more inclined to seek medical assistance and receive appropriate care, consequently leading to increased diagnosis rates.

For instance, in June 2022, Sanofi, a pharmaceutical company, launched Dupixent, which USFDA approved. Dupixent (dupilumab) is primarily indicated for children aged six months to five years with moderate to severe atopic dermatitis that is inadequately controlled with topical prescription therapies or when such therapies are not recommended.

Request Sample Report: 

https://bit.ly/3VjOYsU

Segmentation Overview:

The global atopic dermatitis market has been segmented into drug class, route of administration, age group, and region. Based on drug class, the market segmentation comprises corticosteroids, calcineurin inhibitors, PDE4 Inhibitors, biologics, and others. Corticosteroids are expected to dominate the market growth in the forecast period owing to their anti-inflammatory properties. Based on the route of administration, the market is further segmented as Topical, Oral, and Injectable. Injectable registered a huge growth in 2023 and is expected to dominate the market growth in the forecast period owing to the increasing approvals of injectable drugs such as Dupilumab. This monoclonal antibody targets the interleukin-4 receptor alpha and reduces inflammation and symptoms.

Buy This Research Report: 

https://bit.ly/3IzfZRk

Atopic Dermatitis Market Report Highlights:

  • The global atopic dermatitis market growth is anticipated at a CAGR of 8.3% by 2032.
  • Atopic dermatitis is largely used in the petrochemical, pharmaceutical, and chemical industries to prevent quality loss and wastage of raw materials.
  • The pharmaceutical industry in North America relies on pneumatic conveyor systems to transfer powders and granules in a contamination-free environment, ensuring the quality and purity of pharmaceutical products.
  • Some prominent players in the Atopic dermatitis market report include Atlas Copco AB, Coperion GmbH, Cyclonaire Corporation, Dongyang P & F, Dynamic Air Inc., Flexicon Corporation, Gericke AG, VAC-U-MAX, Schenck Process Holding GmbH, Pneumatic Conveying, Inc., Nol-Tec Systems Inc., Nilfisk Group, Gericke AG.

Industry Trends and Insights:

–          The United States Food and Drug Administration (USFDA) and European Medicines Agency (EMA), play a vital role in drug approval and regulations. The agencies are working to streamline approval processes for innovative therapies while emphasizing patient safety.

–          The rate of Atopic Dermatitis is higher in developed countries. The rate of incidence of developing Atopic Dermatitis is gaining traction in developing countries due to changes in lifestyles, socioeconomic factors, and climate change.

–          The condition is more common in children owing to unspecified reasons. However, it is also becoming more prevalent in adults.

 

Looking Exclusively For Region/Country Specific Report?

https://bit.ly/3Vfb93e

OR

Ask For Discount 

https://bit.ly/43ew6gJ

Atopic dermatitis Market Segmentation:

By Drug Class: Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics and Others

By Route of Administration: Topical, Oral, and Injectable

By Age Group: Pediatric and Adult

By Region: North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. 

 

About DataHorizzon Research:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

Contact:

Mail: [email protected]

Ph: +1-970-672-0390

Website: https://datahorizzonresearch.com/

Follow Us: LinkedIn

Recent Publications:

Healthcare Predictive Analytics Market

Implantable Medical Device Market

Over the Counter (OTC) Drugs Market

Drug Discovery Market

Targeted DNA RNA Sequencing Market

CONTACT: Mail: [email protected] Ph: +1-970-672-0390 Website: https://www.datahorizzonresearch.com 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.